MLAB · Mesa Laboratories Inc /Co/
One customer — 20% of revenue (fiscal 2026)
“In our Clinical Genomics division, a significant portion of revenues is generated from ongoing purchases by a relatively small number of established customers, with a single customer accounting for approximately 20% of the division's revenues in fiscal 2026.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Scientific & Technical Instruments — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MLAB
this stock
Mesa Laboratories Inc /Co/
|
$715.04M | +62.8% | +2.7% | 150.3 | 6.0% |
|
KEYS
Keysight Technologies, Inc.
|
$55.71B | +61.0% | +8.0% | 44.8 | 1.7% |
|
COHR
Coherent Corp.
|
$55.20B | +52.7% | +19.2% | 68.4 | 5.1% |
|
GRMN
Garmin Ltd
|
$53.43B | +36.6% | +15.1% | 30.9 | 1.7% |
|
TDY
Teledyne Technologies Inc
|
$28.31B | +19.6% | -4.6% | 29.5 | 2.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MLAB | -1.0% | +24.5% | +61.8% | -0.1% | +62.8% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | -1.1% | +24.9% | +46.7% | -0.5% | +49.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.